This paper is the forty-fifth consecutive installment of the annual anthological review of
research concerning the endogenous opioid system, summarizing articles published during …

Background The COVID-19 pandemic led to an unprecedented relaxation of restrictions on
take-home doses in opioid agonist treatment (OAT). We conducted a mixed methods …

Highlights OAT treatment journeys in our sample were influenced by a broad range of
individual, social and structural factors, with stigma presenting a pervasive barrier to …

Aim This research aimed to describe how the characteristics of deaths following drug use
changed during the COVID-19 pandemic in England, and how this can inform future strategy …

Introduction Drug overdoses have reached a historic milestone of over 100,000 deaths in a
single year, 75,673 related to opioids. The acceleration in opioid‐related deaths coupled …

Background For patients receiving daily opioid agonist treatment (OAT) for opioid
dependence, several countries relaxed treatment guidelines at the beginning of the COVID …

Introduction The COVID-19 pandemic has instigated the development of telemedicine-
mediated provision of medications for opioid use disorder such as buprenorphine and …

Objectives During the COVID-19 pandemic, addiction treatment services received official
guidance asking them to limit face-to-face contact with patients and to prescribe opioid …

Since March 2020, the COVID-19 pandemic has had a disproportionately high toll on
vulnerable populations, coinciding with increased prevalence of alcohol-and drug-related …

Within the addiction field, some advocates support a suite of de-regulatory policies that aim
to reduce harm by providing people who use drugs with a “safe supply” of pharmaceutical …